<code id='C5BC963367'></code><style id='C5BC963367'></style>
      • <acronym id='C5BC963367'></acronym>
      <center id='C5BC963367'><center id='C5BC963367'><tfoot id='C5BC963367'></tfoot></center><abbr id='C5BC963367'><dir id='C5BC963367'><tfoot id='C5BC963367'></tfoot><noframes id='C5BC963367'>
      • <optgroup id='C5BC963367'><strike id='C5BC963367'><sup id='C5BC963367'></sup></strike><code id='C5BC963367'></code></optgroup>
        5. <b id='C5BC963367'><label id='C5BC963367'><select id='C5BC963367'><dt id='C5BC963367'><span id='C5BC963367'></span></dt></select></label></b><u id='C5BC963367'></u>
          <i id='C5BC963367'><strike id='C5BC963367'><tt id='C5BC963367'><pre id='C5BC963367'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-30 08:48:54 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：85
                                  
                                    
          
                                   
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe
          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 
          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?
          advertisement
          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          An innovative path out of biotech’s “valley of death”
                                
                            
          Next article：  
                                      
                                          At least 13 dead in Texas as scorching temps continue
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles